Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma

A population-based study using the National Cancer Institute SEER database

Clancy J. Clark, Christina M. Wood-Wentz, Kaye M. Reid-Lombardo, Michael L. Kendrick, Marianne Huebner, Florencia Que

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objectives: Although lymphatic spread is common in intrahepatic cholangiocarcinoma (ICC), lymphadenectomy is not widely performed as part of operative resection in this disease. The objectives of this study were to assess national trends for lymphadenectomy and its impact on survival in patients with ICC. Methods: The National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) registry was queried to identify patients with ICC (n= 4893) reported during 1988-2007. Kaplan-Maier and Cox proportional hazards regression were used to analyse survival. Results: Five-year overall survival (OS) was 5.2%. Lymph node (LN) status was available for 48.9% (n= 2391) of patients. Histologic LN evaluation was performed in 13.5% (n= 658) of patients for a median of two (interquartile range: 1-3) LNs. During the study period, the frequency of histologic LN assessment (P= 0.78) did not change in liver resection patients. In the 733 resected patients, positive vs. negative LN status was associated with worse 5-year OS of 8.4% vs. 25.9%, respectively (hazard ratio = 1.8; P < 0.001). Conclusions: Nodal status is an important prognostic factor for survival in patients diagnosed with ICC. In the USA, few patients undergo hepatic resection with lymphadenectomy; therefore, the clinical benefit of formal lymphadenectomy in ICC remains unknown.

Original languageEnglish (US)
Pages (from-to)612-620
Number of pages9
JournalHPB
Volume13
Issue number9
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Cholangiocarcinoma
National Cancer Institute (U.S.)
Lymph Node Excision
Epidemiology
Databases
Population
Lymph Nodes
Survival
Therapeutics
Liver
Survival Analysis
Registries

Keywords

  • cholangiocarcinoma
  • outcomes < cholangiocarcinoma
  • resection < cholangiocarcinoma

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma : A population-based study using the National Cancer Institute SEER database. / Clark, Clancy J.; Wood-Wentz, Christina M.; Reid-Lombardo, Kaye M.; Kendrick, Michael L.; Huebner, Marianne; Que, Florencia.

In: HPB, Vol. 13, No. 9, 09.2011, p. 612-620.

Research output: Contribution to journalArticle

Clark, Clancy J. ; Wood-Wentz, Christina M. ; Reid-Lombardo, Kaye M. ; Kendrick, Michael L. ; Huebner, Marianne ; Que, Florencia. / Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma : A population-based study using the National Cancer Institute SEER database. In: HPB. 2011 ; Vol. 13, No. 9. pp. 612-620.
@article{75c9cb7d734440ee9afc6b6f907f52a8,
title = "Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma: A population-based study using the National Cancer Institute SEER database",
abstract = "Objectives: Although lymphatic spread is common in intrahepatic cholangiocarcinoma (ICC), lymphadenectomy is not widely performed as part of operative resection in this disease. The objectives of this study were to assess national trends for lymphadenectomy and its impact on survival in patients with ICC. Methods: The National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) registry was queried to identify patients with ICC (n= 4893) reported during 1988-2007. Kaplan-Maier and Cox proportional hazards regression were used to analyse survival. Results: Five-year overall survival (OS) was 5.2{\%}. Lymph node (LN) status was available for 48.9{\%} (n= 2391) of patients. Histologic LN evaluation was performed in 13.5{\%} (n= 658) of patients for a median of two (interquartile range: 1-3) LNs. During the study period, the frequency of histologic LN assessment (P= 0.78) did not change in liver resection patients. In the 733 resected patients, positive vs. negative LN status was associated with worse 5-year OS of 8.4{\%} vs. 25.9{\%}, respectively (hazard ratio = 1.8; P < 0.001). Conclusions: Nodal status is an important prognostic factor for survival in patients diagnosed with ICC. In the USA, few patients undergo hepatic resection with lymphadenectomy; therefore, the clinical benefit of formal lymphadenectomy in ICC remains unknown.",
keywords = "cholangiocarcinoma, outcomes < cholangiocarcinoma, resection < cholangiocarcinoma",
author = "Clark, {Clancy J.} and Wood-Wentz, {Christina M.} and Reid-Lombardo, {Kaye M.} and Kendrick, {Michael L.} and Marianne Huebner and Florencia Que",
year = "2011",
month = "9",
doi = "10.1111/j.1477-2574.2011.00340.x",
language = "English (US)",
volume = "13",
pages = "612--620",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma

T2 - A population-based study using the National Cancer Institute SEER database

AU - Clark, Clancy J.

AU - Wood-Wentz, Christina M.

AU - Reid-Lombardo, Kaye M.

AU - Kendrick, Michael L.

AU - Huebner, Marianne

AU - Que, Florencia

PY - 2011/9

Y1 - 2011/9

N2 - Objectives: Although lymphatic spread is common in intrahepatic cholangiocarcinoma (ICC), lymphadenectomy is not widely performed as part of operative resection in this disease. The objectives of this study were to assess national trends for lymphadenectomy and its impact on survival in patients with ICC. Methods: The National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) registry was queried to identify patients with ICC (n= 4893) reported during 1988-2007. Kaplan-Maier and Cox proportional hazards regression were used to analyse survival. Results: Five-year overall survival (OS) was 5.2%. Lymph node (LN) status was available for 48.9% (n= 2391) of patients. Histologic LN evaluation was performed in 13.5% (n= 658) of patients for a median of two (interquartile range: 1-3) LNs. During the study period, the frequency of histologic LN assessment (P= 0.78) did not change in liver resection patients. In the 733 resected patients, positive vs. negative LN status was associated with worse 5-year OS of 8.4% vs. 25.9%, respectively (hazard ratio = 1.8; P < 0.001). Conclusions: Nodal status is an important prognostic factor for survival in patients diagnosed with ICC. In the USA, few patients undergo hepatic resection with lymphadenectomy; therefore, the clinical benefit of formal lymphadenectomy in ICC remains unknown.

AB - Objectives: Although lymphatic spread is common in intrahepatic cholangiocarcinoma (ICC), lymphadenectomy is not widely performed as part of operative resection in this disease. The objectives of this study were to assess national trends for lymphadenectomy and its impact on survival in patients with ICC. Methods: The National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) registry was queried to identify patients with ICC (n= 4893) reported during 1988-2007. Kaplan-Maier and Cox proportional hazards regression were used to analyse survival. Results: Five-year overall survival (OS) was 5.2%. Lymph node (LN) status was available for 48.9% (n= 2391) of patients. Histologic LN evaluation was performed in 13.5% (n= 658) of patients for a median of two (interquartile range: 1-3) LNs. During the study period, the frequency of histologic LN assessment (P= 0.78) did not change in liver resection patients. In the 733 resected patients, positive vs. negative LN status was associated with worse 5-year OS of 8.4% vs. 25.9%, respectively (hazard ratio = 1.8; P < 0.001). Conclusions: Nodal status is an important prognostic factor for survival in patients diagnosed with ICC. In the USA, few patients undergo hepatic resection with lymphadenectomy; therefore, the clinical benefit of formal lymphadenectomy in ICC remains unknown.

KW - cholangiocarcinoma

KW - outcomes < cholangiocarcinoma

KW - resection < cholangiocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=80051875767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051875767&partnerID=8YFLogxK

U2 - 10.1111/j.1477-2574.2011.00340.x

DO - 10.1111/j.1477-2574.2011.00340.x

M3 - Article

VL - 13

SP - 612

EP - 620

JO - HPB

JF - HPB

SN - 1365-182X

IS - 9

ER -